Racura Oncology Ltd

$1.950

Day Range

$1.920 – $1.980

52 Week Range

$1.135 – $4.900

Volume

0.00

Avg Volume (10D)

84.35K

Market Cap

$382.33M

Price Chart

Market Statistics

Open$1.950

Previous Close$1.950

Day High$1.980

Day Low$1.920

52 Week High$4.900

52 Week Low$1.135

Valuation

Market Cap382.33M

Shares Outstanding196.07M

Price to Book14.96

Trading Activity

Volume0.00

Value Traded0.00

Bid$2.000 × 232

Ask$1.990 × 146

Performance

1 Day1.04%

5 Day-4.88%

13 Week-26.42%

52 Week68.10%

YTD-28.57%

Technical Indicators

RSI (14)33.12

50-Day SMA$2.299

200-Day SMA$2.647

Racura Oncology Treats First Patient in Harness-1 EGFRm Lung Cancer Trial

Racura Oncology starts Harness-1 Phase 1 with first patient dosed for RC220 + osimertinib in EGFR-mutant NSCLC; early safety data awaited.

By Imelda Cotton··1 min read min read

Biotechnology

Racura Oncology Advances CPACS Trial to Next Dose Level

Racura Oncology advances RC220 CPACS trial to 80mg/m2 as SRC clears Cohort 2; updated cardioprotection protocol; A$19.38m cash runway to CY2027.

By Isla Campbell··1 min read min read

Biotechnology

Racura Oncology Advances Lung Cancer Program with HARNESS-1 Trial Approval

Racura Oncology wins HARNESS-1 Phase 1a/b governance approval for RC220/osimertinib in EGFR-mutant NSCLC, enabling site initiation and recruitment.

By Isla Campbell··1 min read min read

Biotechnology

Race Oncology Identifies Breakthrough Anticancer Mechanism for Bisantrene (RCDS1)

Race Oncology (ASX: RAC) has discovered the primary anticancer mechanism of action for its lead drug candidate (E,E)-bisantrene, also known as RCDS1. New studies show the compound acts by binding to special DNA and RNA structures called G-quadruplexes, or G4s, which regulate many cancer-driving genes including the master switch MYC. Chief executive officer Dr Daniel Tillett […]

By Nik Hill··2 min read min read